CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Biotechnology & Medical Research

Delayed Hong Kong S.E. 11:45:50 2024-05-27 pm EDT 5-day change 1st Jan Change
1.22 HKD -3.94% Intraday chart for CStone Pharmaceuticals -8.27% -46.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CStone Pharmaceuticals to License Anti-Cancer Drug in 19 European Countries MT
CStone Pharmaceuticals Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website CI
Cstone Pharmaceuticals To Present Cancer Results at 2024 ASCO MT
Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25% MT
Cstone Pharmaceuticals’ CEO Boosts Stakeholding MT
Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5% MT
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor MT
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA CI
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved MT
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer CI
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25% MT
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million MT
The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million. CI
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6% MT
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21% MT
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma CI
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China MT
CStone Pharmaceuticals Announces Strategic Partnership and Exclusive Licensing Agreement with Shenyang Sunshine Pharmaceuticals Co., Ltd for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China CI
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3Sbio for Nofazinlimab (ANTI-PD-1 Antibody) in Mainland China CI
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma CI
China Approves CStone's Lymphoma Medication MT
CStone Pharmaceutical Awaits Chinese Approval for Anti-Cancer Drug MT
CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma CI
CStone CEO to Boost Share Count; Shares Fall 9% MT
Chart CStone Pharmaceuticals
More charts
CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.178 CNY
Average target price
2.698 CNY
Spread / Average Target
+128.97%
Consensus
  1. Stock Market
  2. Equities
  3. 2616 Stock
  4. News CStone Pharmaceuticals
  5. Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%